Safety and Efficacy of Andecaliximab (GS‐5745) Plus Gemcitabine and Nab‐Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study

BACKGROUND: Matrix metalloproteinase 9 (MMP9) expression in the tumor microenvironment is implicated in multiple protumorigenic processes. Andecaliximab (GS‐5745), a monoclonal antibody targeting MMP9 with high affinity and selectivity, was evaluated in combination with gemcitabine and nab‐paclitaxe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Bendell, Johanna, Sharma, Sunil, Patel, Manish R., Windsor, Kevin S., Wainberg, Zev A., Gordon, Michael, Chaves, Jorge, Berlin, Jordan, Brachmann, Carrie Baker, Zavodovskaya, Marianna, Liu, JieJane, Thai, Dung, Bhargava, Pankaj, Shah, Manish A., Khan, Saad A., Starodub, Alexander
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2020
Aiheet:
Gastrointestinal Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648353/
https://ncbi.nlm.nih.gov/pubmed/32812320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0474
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia